Veracyte, which sells molecular diagnostic tests for thyroid cancer to reduce unnecessary surgeries, raised $65 million by offering 5.0 million shares at $13, the low end of the range of $13 to $15. The company originally planned to offer 4.7 million shares. Veracyte plans to list on the NASDAQ under the symbol VCYT. Veracyte initially filed confidentially on 8/13/2013. Morgan Stanley and Leerink Swann acted as lead managers on the deal.
